和邦生物
(603077)
| 流通市值：154.55亿 | | | 总市值：154.55亿 |
| 流通股本：88.31亿 | | | 总股本：88.31亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,725,715,319.77 | 8,547,476,550.13 | 6,813,692,192.92 | 4,848,440,513.18 |
| 营业收入 | 1,725,715,319.77 | 8,547,476,550.13 | 6,813,692,192.92 | 4,848,440,513.18 |
| 二、营业总成本 | 1,693,064,580.46 | 8,490,183,101.47 | 6,550,036,297.8 | 4,604,210,077.7 |
| 营业成本 | 1,541,010,536.39 | 7,880,674,861.75 | 6,084,665,992.82 | 4,306,910,058.74 |
| 税金及附加 | 15,281,731.22 | 69,244,050.1 | 51,870,369.73 | 38,620,430.69 |
| 销售费用 | 18,461,525.73 | 79,251,228.32 | 54,203,613.62 | 33,218,491.64 |
| 管理费用 | 98,313,507.2 | 415,405,917.14 | 304,668,291.44 | 195,640,133.26 |
| 研发费用 | 4,536,209.31 | 30,625,896.07 | 22,518,887.99 | 14,793,583.58 |
| 财务费用 | 15,461,070.61 | 14,981,148.09 | 32,109,142.2 | 15,027,379.79 |
| 其中:利息费用 | 27,558,396.96 | 66,987,144 | 60,444,305.77 | 37,103,561.37 |
| 其中:利息收入 | 10,380,396.9 | 47,050,375.06 | 30,231,339.88 | 17,996,096.84 |
| 加:投资收益 | -1,621,149.03 | -5,670,300.35 | -1,258,619.26 | -300,197.85 |
| 资产处置收益 | 1,238,730.99 | 1,168,756.89 | -23,698.1 | -36,244.07 |
| 资产减值损失(新) | -8,439,376.79 | -128,021,291.49 | -6,531,466.9 | -3,927,034.19 |
| 信用减值损失(新) | -7,366,037.14 | -2,689,460.22 | -9,321,151.14 | -5,920,773.67 |
| 其他收益 | 4,421,189.35 | 16,126,285.6 | 13,778,779.35 | 11,721,112.7 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 20,884,096.69 | -61,792,560.91 | 260,299,739.07 | 245,767,298.4 |
| 加:营业外收入 | 1,262.69 | 1,072,193.37 | 27,901.58 | 17.36 |
| 减:营业外支出 | 241,348.28 | 4,963,194.52 | 826,181.95 | 446,438.64 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 20,644,011.1 | -65,683,562.06 | 259,501,458.7 | 245,320,877.12 |
| 减:所得税费用 | 13,108,894.2 | 5,061,047.87 | 63,964,479.66 | 57,272,517.57 |
| 六、净利润 | 7,535,116.9 | -70,744,609.93 | 195,536,979.04 | 188,048,359.55 |
| 持续经营净利润 | 7,535,116.9 | -70,744,609.93 | 195,536,979.04 | 188,048,359.55 |
| 归属于母公司股东的净利润 | 12,517,312.95 | 31,464,685.07 | 221,318,621.02 | 192,269,822.59 |
| 少数股东损益 | -4,982,196.05 | -102,209,295 | -25,781,641.98 | -4,221,463.04 |
| (一)基本每股收益 | 0 | 0 | 0.03 | 0.02 |
| (二)稀释每股收益 | 0 | 0 | 0.03 | 0.02 |
| 八、其他综合收益 | 14,505,248.27 | -56,289,225.8 | -33,076,482.29 | -16,366,171 |
| 归属于母公司股东的其他综合收益 | 12,268,350.6 | -56,934,716.93 | -31,653,244.96 | -16,529,622.57 |
| 九、综合收益总额 | 22,040,365.17 | -127,033,835.73 | 162,460,496.75 | 171,682,188.55 |
| 归属于母公司股东的综合收益总额 | 24,785,663.55 | -25,470,031.86 | 189,665,376.06 | 175,740,200.02 |
| 归属于少数股东的综合收益总额 | -2,745,298.38 | -101,563,803.87 | -27,204,879.31 | -4,058,011.47 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-31 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |